Connect with us

Awareness

The GMO Agenda Takes a Menacing Leap Forward with EPA’s Silent Approval of Monsanto/Dow’s RNAi Corn

Published

on

Article written by Written by Sayer Ji, founder of Greenmedinfo.com, a reviewer at the International Journal of Human Nutrition and Functional Medicine, Co-founder and CEO of Systome Biomed, Vice Chairman of the Board of the National Health Federation, Steering Committee Member of the Global Non-GMO Foundation

advertisement - learn more

Without much more than a whisper from the mainstream media, Monsanto’s newest Frankenfood has received full EPA approval and will be arriving on dinner plates by the end of the decade. The implications of this are harrowing, to say the least.

While you may not have made up your mind on the dangers of GMOs, you likely feel entitled to know when you’re consuming a food that is the product of laboratory research. For this reason, I am reporting on Monsanto’s latest food technology, unfortunately, already in the pipeline. And quite silently so. I write this with a certain degree of solemnity, if not also a tinge of regret, because, for three years, I have heard rumblings of Monsanto’s next project – RNA interference technology. It was actually the late Heidi Stevenson, my friend, colleague, and founder of the platform Gaia Health, who first alerted me to the dangers of RNA interference-based tinkering with our food supply when she reported on the near disastrous approval of GMO wheat using RNA interference technology in Australia. Thankfully a few brave scientists and informed public stood up and, together, averted the disaster. But since then, both the dangers and the breakneck speed of development of this technology have gone largely ignored, even among activists deep in the non-GMO movement. In order to truly appreciate the gravity of the situation, and why the EPA’s approval of RNAi corn intended for human consumption, is so concerning, it will first require a little background information on the fascinating topic of non-coding small RNAs, and their formidable relevance to our health.

How Non-Coding, Small RNAs Link Together The Entire Biosphere

One of the most important discoveries of our time is that all plants, including those we use for food and animal feed, contain a wide range of RNA molecules capable of inhibiting gene expression or translation. These non-coding RNA molecules neutralize targeted messenger RNA molecules (mRNAs), which prevents their translation into a protein, i.e. they “silence genes.”

Compelling research has surfaced suggesting that not only do these genome-regulating small RNA molecules exist in our foods, but that they are capable of surviving digestion, and being absorbed into our bodies fully intact where they alter, suppress or silence genes, post-transcriptionally. Moreover, some of these small RNAs — primarily microRNAs (miRNAs) and small interfering RNAs (siRNAs) — are believed to be cross-kingdom mediators of genetic information, making it possible for RNAs in one species impacting many others through both their active and passive exposure to them.

Food therefore is essentially an epigenetic modifier of gene expression, making it a form of information, and not only a source of bodily building blocks and caloric energy, as conventionally understood. As such, any significant changes to food or feed staples within our food chain could have powerful impacts on the physiological fate of those consuming them, essentially rewriting the functionality of our genomic hardware via software like changes in RNA profiles. The entire biosphere, therefore, is held together in a web-like fashion through these molecular RNA messengers, lending a plausible mechanism to the biotic aspect of Lovelock and Margulis’ Gaia theory of Earth as a self-regulating, meta-organism. You can learn more by reading my article Genetic Dark Matter, Return of the Goddess, and the Post-Science Era.

advertisement - learn more

Monsanto and Co Capitalizing on RNA interference Technology

While this discovery will have profound implications for the field of nutrition and medicine, it has also created enormous interest among biotech and agricultural firms, namely, Monsanto and Dow, looking to capitalize on the design of proprietary products using interference (RNAi) technology. In mid June, last month Monsanto received EPA approval for a type of corn genetically altered to produce an RNA-based pesticidal agent (aka, a plant-incorporated protectant (PIP)) which lethally targets a metabolic pathway within the corn rootworm, known within the industry as the “billion dollar bug.” Branded as Smartstax PRO, the newly minted GMO plant produces a small, double-stranded RNA known as DvSnf7 dsRNA which disrupts a critical gene within the rootworm, causing its death. This was added on top of four other “stacked” GMO traits, such as the ability to produce two other pesticidal proteins (Cry1A.105 and Cry2Ab2), as well as survive exposure to both glyphosate (aka Monsanto’s Roundup 2) and Glufosinate (aka Dow’s Libertylink), highly toxic herbicides. Roundup, for instance, has demonstrated carcinogenicity in the parts per trillion range. Yet, the EPA considers it perfectly safe for consumers to ingest many orders of magnitude higher concentrations than that, proving its function as a cheerleader and not a regulator of the industry that controls our food supply.

The Atlantic, one of the only mainstream news outlets to report on the topic, pointed out how surprisingly low key the approval process was:

“The EPA’s decision attracted little attention from the press or even from environmental groups that reliably come out against new genetically modified crops.”

Bill Freese, The Center for Food Safety’s science policy analyst, told the Atlantic he was caught off guard by EPA’s decision to only allow 15 days of public comment, and the fact that it did not post its decision to the Federal Register, as it customary, especially considering how unprecedented the use of a RNAi insecticide in a plant intended for human consumption is. Monsanto anticipates the new corn will be on the market by the end of the decade.

One would imagine that such revolutionary technology would require short and long-term (decades) of safety testing before licensure. Instead, as is often the case with big-ticket market agendas, the product is being rushed to market. There are already significant biases in place within the EPA and USDA in regard to nucleic acids – assumptions that exempt them from cautionary considerations. RNA is considered Generally Accepted As Safe (GRAS), but this is because it is defined and perceived only as a physical substance rather than as the powerful signaling/informational molecule it is. The EPA’s approval of RNAi food crops ignores the fact that it takes a multi-generational timescale to understand the influence of epigenetic modifiers on the genome of a species, much less the human species, whose timescale is orders of magnitude beyond animal models used to establish much of the risk/benefit data used in pre-approval evaluations. RNAi interference technology promises specificity — one RNAi molecule change equals one gene suppressed — but ignores the virtually infinite possibility of unintended, adverse effects in what are incomprehensibly complex biological systems. Indeed, researchers have warned that RNAi can not only profoundly affect gene expression, but that the changes it induces can permanently alter a species through inherited traits 1:

“Once a silencing effect is initiated, the effect may be inherited. The biochemistry of this process varies depending on the organism and remains an area of active research with many unknown aspects. Nevertheless, it is known for example that human cells can maintain the modifications necessary for TGS, creating actual or potential epigenetic inheritance within tissues and organisms (Hawkins et al., 2009). In some cases the dsRNA pathways induce RNA-dependent DNA methylation and chromatin changes (TGS) that persist through reproduction or cell division, and in other cases the cytoplasmic pathways remain active in descendents (Cogoni and Macino, 2000).”

GM Technology and Unintended Consequences

Indeed, critics of RNA interference technology make the point that RNAi technology aims to target the production of a specific protein by identifying the sequence in question. But two or more genes can have sequence homologies. This means, as applies to the use of RNA interference in medicine, a gene that is targeted to turn off a “disease-causing gene” could have a number of off-target effects, one of which w

Criticisms of RNAi in the agricultural sector are long-standing among the highly informed. For instance, Jonathan Latham, Ph.D. and Allison Wilson, Ph.D., wrote a seminal paper on the topic over a decade ago titled “Off-target effects of plant transgenic RNAi: three mechanisms lead to distinct toxicological and environmental hazards,” wherein 3 of the primary safety concerns are addressed: 1) Off target effects leading to non-specific down-regulation of plant RNAs 2) Off target effects affecting non-target invertebrates feeding on plant material 3) potential effects on mammals. In mammals, long (>30 bp) perfectly duplexed RNAs (such as are typically produced by plant RNAi transgenes) are Pathogen Associated Molecular Patterns (PAMPS) and are consequently highly potent triggers of innate anti-viral defences. The effects of long dsRNAs on mammalian cellular functions are typically profound and extend to complete inhibition of protein translation and cell death. Nevertheless, the implications of such molecules in  the mammalian diet have hardly been tested.

That’s quite a serious list of concerns. As you can see, concern #3 includes the possibility that these dsRNAs may lead to protein translation and cell death. Clearly if the EPA has declared Monsanto and Dow’s new RNAi corn safe for human consumption, they would need to prove this a non-issue.

Monsanto Falling On Their Own ‘Peer-Reviewed’ Sword

Surprisingly, Monsanto itself has produced one of the most damning papers on the topic yet. Several years ago I stumbled upon a study funded by Monsanto that raised a number of red flags for me. Titled, “Endogenous small RNAs in grain: Semi-quantification and sequence homology to human and animal genes,” researchers employed by Monsanto in their St. Louis, MO, laboratory analyzed the presence of endogenous small RNAs in common food and feed staples — soybeans, corn, rice — discovering that hundreds of these plant RNAs had a perfect 100% complementary match to human genes as well as other mammals.

Why is this significant? Endogenous small RNAs, such as small interfering RNAs (siRNAs) and microRNAs (miRNAs), are effector molecules of RNA interference (RNAi), which is a gene suppression mechanism found in plants, mammals, and other eukaryotes. The implication, therefore, of Monsanto’s finding is that plant RNAs — were they capable of surviving digestion and accumulating in target tissues to physiologically relevant concentrations — are capable of epigenetically silencing hundreds of genes within the human body. Below you will find a list of the RNA/gene matches between rice and the human genome:

Despite the abundance of perfect 100% complementarity matches listed above, Monsanto’s conclusion was a conveniently pollyannish dismissal of the safety implications of these findings, stating that:

“The abundance of endogenous small RNA molecules in grain from safely consumed food and feed crops such as soybean, corn, and rice and the homology of a number of these dietary small RNAs to human and animal genomes and transcriptomes establishes a history of safe consumption for dietary small RNAs.” 

While this may be true for traditionally used plants, it does not follow that genetically modified organisms would necessarily be safe because non-GMO versions are. [The pseudo-scientific conceptual ploy of “substantial equivalency behind traditional and GMO cultivars has been the basis for the approval of GMOs since their inception.] Monsanto’s conclusion relates to the fact that it has invested a great amount of resources into developing proprietary RNAi-based organisms which help it to maintain and further expand its monopolizing control on the global food supply.

Additionally, one of their primary justifications for concluding the safety of endogenous plant RNAs on human health was that: “…there does not appear to be any evidence in the scientific literature suggesting that intact RNA is absorbed following ingestion.” This bold claim has been disproven. The Monsanto paper was written in 2008, 3 years before the groundbreaking discovery of Zhang et al published in the Cell Research, entitled,”Exogenous plant MIR168a specifically targets mammalian LDLRAP1: evidence of cross-kingdom regulation by microRNA,” wherein it was demonstrated that human subjects fed rice containing the microRNA MIR168a have measurable amounts of it present in their blood and tissue, and that it binds to the lipoprotein receptor adapter protein in the liver. More succinctly:

“These findings demonstrate that exogenous plant miRNAs in food can regulate the expression of target genes in mammals.”

Since then, a hotly contested debate has ensued, which is understandable, given the increasingly politicized and financially-motivated nature of scientific debate and findings.

Here’s Monsanto’s conclusion about the safety of RNAi-based food technology:

“Based on this evidence it can be concluded that RNAi-mediated regulation of gene expression in biotechnology-derived crops is as safe for food and feed use as conventional crops that harness RNAi-based gene regulation as one of several ways to achieve new plant traits. The safety of future crops generated through applications of RNAi should thus be evaluated for safety using the existing comparative safety assessment paradigm, which has been developed for biotechnology-derived Crops.”

First of all, the “evidence” they are referring to is based on an axiomatic absurdity: equating the absence of evidence with evidence of absence. In other words, you can’t prove this negative: “that a hazard does not exist” because positivistic proof of anything requires that you demonstrating something, not nothing.

Let’s also not overlook the conflict of interest statement at the end of their paper: “All authors are employees of the Monsanto Company. The  Monsanto Company is an agricultural company that produces,” which speaks to Monsanto’s long history of funding science that denies safety risks of their products, such as the Roundup-Cancer link, which now even the California EPA accepts as fact.

The Heart of the Problem

In a seminal paper published in 2016 in Trends in Microbiology, entitled, “How Our Other Genome Controls Our Epi-Genome,” it is proposed that the very RNAs biotech/agrochemical companies like Monsanto and Dow are tinkering with in our food should be reconsidered as part of the definition of our species versus the conventional view that it is just something informationally inert that we eat and exists “out there.” Using a revised version of Da Vinci’s Vitruvian man, as pictured below, they propose that there are 4 inseparable parts of our species: 1) human cells 2) human microbiota and other bacteria 3) Fungi and Viruses 4) Food.

As you can see, because of the interconnectivity and “social networking” functionalities of RNAs packaged in microvesicles called exosomes, all four parts of this new definition of man become united in an indivisible whole. Because these RNAs packed in edible exosomesepigenetically active, the food we eat “literally talks to our mRNA and DNA,” as I have explained in greater detail here:  “Amazing Food Science Discovery: Edible Plants ‘Talk’ To Animal Cells, Promote Healing.”

As we have seen in Monsanto’s own paper on the topic, foods contain hundreds of small RNAs whose 100% complementarity match with human genes imply they can directly impact, and even silence those genes. This silencing is not necessarily “bad,” but it is clear that we are tinkering with a design that we are only just beginning to understand, much less know how to ascertain the risks of and properly regulate. But, considering that Monsanto’s research reveals how intricately connected the human and the food genomes are are — and furthermore, that post-2008 research has surfaced showing Monsanto was wrong and plant RNAs from food do have direct impacts on human genome/epigenome expression — it is highly irresponsible for them to continue to claim that food manipulation technologies will not have unintended, adverse effects in principle. Sadly, with the EPAs approval of four new RNAi forms of corn already completed, and likely many more on the way, we may be stuck with secondary and much slower forms of recourse: post-marketing, epidemiological surveillance of exposed populations, where patterns of disease can take decades if not generations to surface — and then with so many confounding factors at play, not with any certainty.

That said, I believe education and the awareness it generates is our best bet at countermanding the widespread acceptance of this highly experimental and obviously dangerous form of genetic engineering. As has been the case recently with glyphosate being classified as a carcinogen by the California EPA, and a growing mainstream movement to fight the forced feeding of non-labeled GMO laden products (March Against Monsanto), the tides are turning. Please help us spread this information far and wide.

Sign Up For The Newsletter

*This work is reproduced and distributed with permission of GreenMedInfo LLC. Want to learn more from GreenMedInfo? Sign up for the newsletter here: http://www.greenmedinfo.com/greenmed/newsletter

References

Heinemann JA, Agapito-Tenfen SZ, Carman JA. A comparative evaluation of the regulation of GM crops or products containing dsRNA and suggested improvements to risk assessments. Environ Int. 2013 May;55:43-55. doi: 10.1016/j.envint.2013.02.010. Epub 2013 Mar 20. PubMed PMID: 23523853.

 

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Advertisement
advertisement - learn more

Awareness

Long-Term Consequences of Mumps Vaccination: Many Unanswered Questions

Published

on

This is Part II of a two-part series on mumps. Part I discussed how mumps vaccination and the flawed mumps component of Merck’s MMR vaccine are fostering dangerous mumps outbreaks in adolescents and young adults.

It has been about five decades since the U.S. Food and Drug Administration (FDA) approved Merck’s first mumps vaccine. The company began launching combination MMR (measles, mumps and rubella) vaccines in the 1970s. Coincidentally—or not—an infertility crisis has been brewing over roughly the same time period, with dramatic declines in sperm counts and record-lowfertility levels. However, few investigators seem interested in assessing whether mumps outbreaks in highly vaccinated populations of teens and young adults could be having long-termeffects on fertility or other health indicators.

As described in Part I, childhood MMR vaccination has been an unmitigated disaster where mumps is concerned, deferring mumps infection to older ages and leaving adolescents and young adults vulnerable to serious reproductive complications. Public health reports show that the vast majority of mumps cases and outbreaks occur in youth who have been fully vaccinatedwith the prescribed two-dose MMR series, supporting a hypothesis of “waning immunity after the second dose.” FDA and Centers for Disease Control and Prevention (CDC) officials even admitthat mumps outbreaks in the post-vaccination era “typically involve young adults,” and that vaccination is failing to protect those who are college-age and above.

Myopically, many vaccine experts have called for a third MMR dose—or even “booster dosing throughout adulthood”—even though the FDA’s and CDC’s own research shows that MMR boosters in college-age youth barely last one year. As alleged in whistleblower lawsuits wending their way through the courts over the past eight years, Merck presented the FDA with a “falsely inflated efficacy rate” for the MMR’s mumps component, using animal antibodies and other fraudulent tactics to fool FDA—and the public—into believing that the vaccine was effective.

When infection arises after puberty, however, mumps is no laughing matter, presenting an increased risk of complications such as hearing loss, encephalitis and inflammation of the reproductive organs.

Mumps after puberty is no laughing matter

Around the time that the first mumps vaccine came on the market, the 1967 children’s classic The Great Brain humorously depicted mumps infection in childhood as a mere nuisance. The book’s young protagonist goes out of his way to intentionally infect himself with mumps so that he can beat his two brothers to the recovery finish line—and he experiences no adverse consequences other than his siblings’ annoyance.

advertisement - learn more

When infection arises after puberty, however, mumps is no laughing matter, presenting an increased risk of complications such as hearing loss, encephalitis and inflammation of the reproductive organs. About one in three postpubertal men with mumps develops orchitis(inflammation of the testes), which can damage sperm, affect testosterone production and contribute to subfertility and infertility. During a mumps outbreak in England in the mid-2000s, mumps orchitis accounted for 42% of all hospitalized mumps cases; the researchers attributed this outcome—which was the most common reason for hospitalization—to “the high attack rates in adolescents and young adults” that occurred “despite high coverage with two-dose MMR.” An analysis of a 2006 mumps outbreak in the U.S. reported that male patients were over three times more likely than female patients to experience complications, “due primarily to orchitis.”

An estimated 5% to 10% of postpubertal women will develop oophoritis (swelling of the ovaries) following mumps infection. Oophoritis is associated with premature menopause and infertility, but mumps-related oophoritis has garnered little notice.

Mumps infections are often asymptomatic or produce nonspecific symptoms such as fever, while cases of orchitis may present with no other mumps symptoms. Nonetheless, public health officials advise clinicians that orchitis is an instant cue to test for mumps virus, and testing often reveals elevated mumps antibodies. In a case report of MMR failure, British clinicians isolated a novel genetic strain of mumps virus from the patient’s semen two weeks after the onset of orchitis and found mumps RNA in the semen 40 days later; they also noted “the appearance of anti-sperm antibodies,” with “potential long-term adverse effects on the patient’s fertility.”

In 2017, researchers who reviewed 185 studies conducted in Western nations found that sperm counts had plummeted by 50% to 60% between 1973 and 2011—an average decrease of 1.4% annually. Commenting on this work, one analyst estimated that 20% to 30% of young men in Europe and North America have sperm concentrations associated with a reduced ability to father a child. Given estimates that as much as 40% of reproductive problems have to do with the male partner, there is agreement on the importance of “finding and eliminating [the] hidden culprits in the environment” that most researchers believe are to blame.

An estimated 5% to 10% of postpubertal women will develop oophoritis (swelling of the ovaries) following mumps infection. Oophoritis is associated with premature menopause and infertility, but mumps-related oophoritis has garnered little notice.

MMR’s and MMRV’s potential to impair fertility never studied

Merck has not evaluated either of its two MMR vaccines—the MMR-II and the MMR-plus-varicella (MMRV) vaccine—for their potential to impair fertility. Whether such testing would unearth direct effects on fertility (as appears to be possible with HPV vaccination in women) is thus unknown. However, mumps vaccination undeniably increases reproductive-age individuals’ risk of mumps infection and, in the process, increases the risk of fertility-altering complications. These facts alone should be attracting far more attention.

Unfortunately, because clinicians already tend to underdiagnose mumps infection and underestimate mumps complications, it is likely that they are failing to recognize possible vaccine-induced reproductive health consequences of mumps infection in their adolescent and young adult patients. In one university outbreak, “most physicians…did not suspect mumps,” and even when they became aware of the outbreak, “diagnosing mumps was not always straightforward.” Moreover, although differentiating between vaccine strains of mumps virus and wild types could provide valuable information, few clinicians have the capacity or inclination to perform testing of this type. A Japanese study of cerebrospinal fluid and saliva from patients with mumps complications found vaccine strain in nearly all of the samples and noted the information’s importance in helping determine whether the complications were vaccine-related.

Those who have sought to understand mumps vaccines’ poor performance point to a mixture of explanatory factors. These include waning immunity, the high population density and close quarters encountered in settings such as college campuses, incomplete vaccine-induced immunity to wild virus as well as viral evolution such that “the vaccine triggers a less potent reaction against today’s mumps viruses than those of 50 years ago.” However, some also quietly admit that individuals with “mild vaccine-modified disease” could be perpetuating the chain of transmission. This latter point ought to be raising questions about the logic and wisdom of administering further rounds of MMR boosters during outbreaks while ignoring the problems created by the doses already given.

… some individuals respond poorly to mumps vaccination and vaccine-induced antibody levels correlate poorly with protection from mumps infection, irrespective of the number of additional doses of mumps-containing vaccine they receive.

Most scientists appear to be either resigned to ongoing mumps outbreaks in vaccinated populations or actually accept periodic outbreaks as the cost of doing business. Publications by FDA and CDC researchers reveal these agencies’ awareness that some individuals respond poorly to mumps vaccination and that vaccine-induced antibody levels correlate poorly with protection from mumps infection, “irrespective of the number of additional doses of mumps-containing vaccine they receive.” Considering the effects on fertility, the generally abysmal track record of mumps vaccination and Merck’s fraudulent claims about efficacy, it is hard to fathom medical and public health experts’ complacency about current mumps vaccines and vaccine policies.


Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. CHD is planning many strategies, including legal, in an effort to defend the health of our children and obtain justice for those already injured. Your support is essential to CHD’s successful mission.

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Continue Reading

Alternative News

Legal Challenge Against Forced Vaccination Filed in New York City

Published

on

On April 15, 2019, a legal challenge was filed in the New York State Trial Court by Robert Krakow, Robert F. Kennedy, Jr. and Patricia Finn against the New York City Department of Health and Human Hygiene for their forced Measles-Mumps-Rubella vaccination. The legal team asked for a temporary restraining order against the mandate that the Judge will likely review and provide an ex parte decision. Children’s Health Defense is supporting these efforts.

Last week, Children’s Health Defense reported that the NYC Commissioner of Health declared a public health emergency, ordering all people who live, work or reside in four Brooklyn zip codes to be vaccinated with the Measles-Mumps-Rubella vaccine. Non-compliance with the order is a misdemeanor subject to criminal and civil fines, including imprisonment. Only those with documented immunity, medical contraindications or infants under six months are exempt from the vaccine mandate.

READ THE PETITION
READ THE MEMORANDUM OF LAW
READ THE AFFIRMATION

Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. CHD is planning many strategies, including legal, in an effort to defend the health of our children and obtain justice for those already injured. Your support is essential to CHD’s successful mission.

advertisement - learn more

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Continue Reading

Awareness

Magnesium Puts Psychiatric Drugs to Shame for Depression

Published

on

In Brief

  • The Facts:

    This article was written by Sayer Ji, Founder of Greenmedinfo.com where this article first appeared. Posted here with permission.

  • Reflect On:

    Is the priority of our federal health regulatory agencies and pharmaceutical companies human health, or profit? If there are more effective ways to treat several illnesses, why do they never mention them?

Depression is one of the most widely diagnosed conditions of our time, with over 3 million cases in the U.S. every year, and 350 million believed affected worldwide.1 Conventional medicine considers antidepressant drugs first-line treatments, including the newly approved injected postpartum drug costing $34,000 a treatment, to the tune of a 16 billion dollars in global sales by 2023. Despite their widespread use, these drugs are fraught with a battery of serious side effects, including suicidal ideation and completion — the last two things you would hope to see in a condition that already has suicidality as a co-morbidity. For this reason alone, natural, safe, and effective alternatives are needed more than ever before.

While research into natural alternatives for depression is growing daily — GreenMedInfo.com’s Depression database contains 647 studies on over 100 natural substances that have been studied to prevent or treat depression — it is rare to find quality human clinical research on the topic published in well-respected journals. That’s why a powerful study published in PLOS One titled, “Role of magnesium supplementation in the treatment of depression: A randomized clinical trial,” is so promising. Not only is magnesium safe, affordable, and easily accessible, but according to this recent study, effective in treating mild-to moderate symptoms of depression.

While previous studies have looked at the association between magnesium and depression,2-7 this is the first placebo-controlled clinical study to evaluate whether the use of over-the-counter magnesium chloride (248 mg elemental magnesium a day for 6 weeks) improves symptoms of depression.

The study design was a follows:

“ An open-label, blocked, randomized, cross-over trial was carried out in outpatient primary care clinics on 126 adults (mean age 52; 38% male) diagnosed with and currently experiencing mild-to-moderate symptoms with Patient Health Questionnaire-9 (PHQ-9) scores of 5–19. The intervention was 6 weeks of active treatment (248 mg of elemental magnesium per day) compared to 6 weeks of control (no treatment). Assessments of depression symptoms were completed at bi-weekly phone calls. The primary outcome was the net difference in the change in depression symptoms from baseline to the end of each treatment period. Secondary outcomes included changes in anxiety symptoms as well as adherence to the supplement regimen, appearance of adverse effects, and intention to use magnesium supplements in the future. Between June 2015 and May 2016, 112 participants provided analyzable data.”

The study results were as follows:

advertisement - learn more

“Consumption of magnesium chloride for 6 weeks resulted in a clinically significant net improvement in PHQ-9 scores of -6.0 points (CI -7.9, -4.2; P<0.001) and net improvement in Generalized Anxiety Disorders-7 scores of -4.5 points (CI -6.6, -2.4; P<0.001). Average adherence was 83% by pill count. The supplements were well tolerated and 61% of participants reported they would use magnesium in the future. Similar effects were observed regardless of age, gender, baseline severity of depression, baseline magnesium level, or use of antidepressant treatments. Effects were observed within two weeks. Magnesium is effective for mild-to-moderate depression in adults. It works quickly and is well tolerated without the need for close monitoring for toxicity.”

 For perspective, conventional antidepressant drugs are considering to generate an “adequate or complete treatment response” with a PHQ-9 score “decrease of 5 points or more from baseline.” At this level of efficacy, their recommended action is: “Do not change treatment; conduct periodic follow-up.” The magnesium’s score of -6.0 therefore represents the height of success within conventional expectations for a complete response, which is sometimes termed “remission.” In contradistinction, conventional antidepressant drugs result in nearly half of patients discontinuing treatment during the first month, usually due to their powerful and sometimes debilitating side effects.8

To summarize the main study outcomes:

  • There was a clinically significant improvement in both Depression and Anxiety scores.
  • 61% of patients reported they would use magnesium in the future.
  • Similar effects occurred across age, gender, severity of depression, baseline magnesium levels, or use of antidepressant treatments.
  • Effects were observed within two weeks.

 The study authors concluded:

“Magnesium is effective for mild-to-moderate depression in adults. It works quickly and is well tolerated without the need for close monitoring for toxicity.”

Beyond Depression: Magnesium’s Many Health Benefits & Where To Source It

Magnesium is a central player in your body’s energy production, as its found within 300 enzymes in the human body, including within the biologically active form of ATP known as MG-ATP. In fact, there have been over 3,751 magnesium binding sites identified within human proteins, indicating that it’s central nutritional importance has been greatly underappreciated.

Research relevant to magnesium has been accumulating for the past 40 years at a steady rate of approximately 2,000 new studies a year. Our database project has indexed well over 100 health benefits of magnesium thus far.  For the sake of brevity, we will address seven key therapeutic applications for magnesium as follows:

  • Fibromyalgia: Not only is magnesium deficiency common in those diagnosed with fibromyalgia, 9,10 but relatively low doses of magnesium (50 mg), combined with malic acid in the form of magnesium malate, has been clinically demonstrated to improve pain and tenderness in those to which it was administered.11
  • Atrial Fibrillation: A number of studies now exist showing that magnesium supplementation reduce atrial fibrillation, either by itself, or in combination with conventional drug agents.12
  • Diabetes, Type 2: Magnesium deficiency is common in type 2 diabetics, at an incidence of 13.5 to 47.7% according to a 2007 study. 13 Research has also shown that type 2 diabetics with peripheral neuropathy and coronary artery disease have lower intracellular magnesium levels. 14 Oral magnesium supplementation has been shown to reduce plasma fasting glucose and raising HDL cholesterol in patients with type 2 diabetes.15 It has also been shown to improve insulin sensitivity and metabolic control in type 2 diabetic subjects.16
  • Premenstrual Syndrome: Magnesium deficiency has been observed in women affected by premenstrual syndrome.17 It is no surprise therefore  that it has been found to alleviate premenstrual symptoms of fluid retention, 18 as well as broadly reducing associated symptoms by approximately 34% in women, aged 18-45, given 250 mg tablets for a 3-month observational period.20 When combined with B6, magnesium supplementation has been found to improve anxiety-related premenstrual symptoms.19
  • Cardiovascular Disease and Mortality: Low serum magnesium concentrations predict cardiovascular and all-cause mortality.21 There are a wide range of ways that magnesium may confer its protective effects. It may act like a calcium channel blocker,22it is hypotensive,23 it is antispasmodic (which may protect against coronary artery spasm),24 and anti-thrombotic.25 Also, the heart muscle cells are exceedingly dense in mitochondria (as high as 100 times more per cell than skeletal muscle), the “powerhouses” of the cell,” which require adequate magnesium to produce ATP via the citric acid cycle.
  • Migraine Disorders: Blood magnesium levels have been found to be significantly lower in those who suffer from migraine attacks.26,27 A recent Journal of Neural Transmission article titled, “Why all migraine patients should be treated with magnesium,” pointed out that routine blood tests do not accurately convey the true body magnesium stores since less than 2% is in the measurable, extracellular space, “67% is in the bone and 31% is located intracellularly.”28The authors argued that since “routine blood tests are not indicative of magnesium status, empiric treatment with at least oral magnesium is warranted in all migraine sufferers.” Indeed, oral magnesium supplementation has been found to reduce the number of headache days in children experiencing frequent migranous headaches,29and when combined with l-carnitine, is effective at reducing migraine frequency in adults, as well.30
  • Aging: While natural aging is a healthy process, accelerated aging has been noted to be a feature of magnesium deficiency,31especially evident in the context of long space-flight missions where low magnesium levels are associated with cardiovascular aging over 10 times faster than occurs on earth.32 Magnesium supplementation has been shown to reverse age-related neuroendocrine and sleep EEG changes in humans.33 One of the possible mechanisms behind magnesium deficiency associated aging is that magnesium is needed to stabilize DNA and promotes DNA replication. It is also involved in healing up of the ends of the chromosomes after they are divided in mitosis.34

 It is quite amazing to consider the afformentioned side benefits of magnesium consumption or supplementation within the context of the well-known side effects of pharmaceutical approaches to symptom

management of disease. On average, conventional drugs have 75 side effects associated with their use, including lethal ones (albeit sometimes rare). When considering magnesium’s many side benefits

and extremely low toxicity, clearly this fundamental mineral intervention (and dietary requirement) puts pharmaceutical approaches to depression to shame.

Best Sources of Magnesium In The Diet

The best source of magnesium is from food, and one way to identify magnesium-containing foods are those which are green, i.e. chlorophyll rich. Chlorophyll, which enable plants to capture solar energy and convert it into metabolic energy, has a magnesium atom at its center. Without magnesium, in fact, plants could not utilize the sun’s light energy.

Magnesium, however, in its elemental form is colorless, and many foods that are not green contain it as well. The point is that when found complexed with food cofactors, it is absorbed and utilized more efficiently than in its elemental form, say, extracted from limestone in the form of magnesium oxide.

 The following foods contain exceptionally high amounts of magnesium. The portions described are 100 grams, or a little over three ounces.

  • Rice bran, crude (781 mg)
  • Seaweed, agar, dried (770 mg)
  • Chives, freeze-dried (640 mg)
  • Spice, coriander leaf, dried (694 mg)
  • Seeds, pumpkin, dried (535 mg)
  • Cocoa, dry powder, unsweetened (499 mg)
  • Spices, basil, dried (422 mg)
  • Seeds, flaxseed (392 mg)
  • Spices, cumin seed (366 mg)
  • Nuts, brazilnuts, dried (376 mg)
  • Parsley, freeze-dried (372 mg)
  • Seeds, sesame meal (346 mg)
  • Nut, almond butter (303 mg)
  • Nuts, cashew nuts, roasted (273 mg)
  • Soy flour, defatted (290 mg)
  • Whey, sweet, dried (176 mg)
  • Bananas, dehydrated (108 mg)
  • Millet, puffed (106 mg)
  • Shallots, freeze-dried (104 mg)
  • Leeks, freeze-dried (156 mg)
  • Fish, salmon, raw (95 mg)
  • Onions, dehydrated flakes (92 mg)
  • Kale, scotch, raw (88 mg)

 Fortunately, for those who need higher doses, or are not inclined to consume magnesium rich foods, there are supplemental forms commonly available on the market. Keep in mind, for those who wish to take advantage of the side benefit of magnesium therapy, namely, its stool softening and laxative properties, magnesium citrate or oxide will provide this additional feature.

For those looking to maximize absorption and bioavailability magnesium glycinate is ideal, as glycine is the smallest amino acid commonly found chelated to magnesium, and therefore highly absorbable.

For more information on natural solutions to resolving depression, download our free e-book on the topic “21st Century Solutions to Depression.” 

References:

1) World Health Organization. Depression fact sheet no. 369 2012 [cited 2016 December 20]. Available from: http://www.who.int/mediacentre/factsheets/fs369/en/.

2) Jacka FN, Overland S, Stewart R, Tell GS, Bjelland I, Mykletun A. Association between magnesium intake and depression and anxiety in community-dwelling adults: the Hordaland Health Study. Aust N Z J Psychiatry. 2009;43(1):45–52. Pmid:19085527.

3) Huang JH, Lu YF, Cheng FC, Lee JN, Tsai LC. Correlation of magnesium intake with metabolic parameters, depression and physical activity in elderly type 2 diabetes patients: a cross-sectional study. Nutrition J. 2012;11(1):41. pmid:22695027; PubMed Central PMCID: PMC3439347.

4) Tarleton EK, Littenberg B. Magnesium intake and depression in adults. J Am Board Fam Med. 2015;28(2):249–56. Pmid:25748766

5) Yary T, Lehto SM, Tolmunen T, Tuomainen T-P, Kauhanen J, Voutilainen S, et al. Dietary magnesium intake and the incidence of depression: a 20-year follow-up study. J Affect Disord. 2016;193:94–8. Pmid:26771950

6) Eby GA, Eby KL. Rapid recovery from major depression using magnesium treatment. Med Hypotheses. 2006;67(2):362–70. pmid:16542786

7) N Engl J Med. 2000 Dec 28;343(26):1942-50. Managing depression in medical outpatients.

8)  Damiano Piovesan, Giuseppe Profiti, Pier Luigi Martelli, Rita Casadio. 3,751 magnesium binding sites have been detected on human proteins. BMC Bioinformatics. 2012 ;13 Suppl 14:S10. Epub 2012 Sep 7. PMID: 23095498

9) G Moorkens, B Manuel y Keenoy, J Vertommen, S Meludu, M Noe, I De Leeuw. Magnesium deficit in a sample of the Belgian population presenting with chronic fatigue. Magnes Res. 1997 Dec;10(4):329-37. PMID: 9513929

10)  J Eisinger, A Plantamura, P A Marie, T Ayavou. Selenium and magnesium status in fibromyalgia. Magnes Res. 1994 Dec;7(3-4):285-8. PMID: 7786692

11)  I J Russell, J E Michalek, J D Flechas, G E Abraham. Treatment of fibromyalgia syndrome with Super Malic: a randomized, double blind, placebo controlled, crossover pilot study. J Rheumatol. 1995 May;22(5):953-8. PMID: 8587088

12) GreenMedInfo.com, Atrial Fibrillation and Magnesium (5 studies)

13)  Phuong-Chi T Pham, Phuong-Mai T Pham, Son V Pham, Jeffrey M Miller, Phuong-Thu T Pham . Hypomagnesemia in patients with type 2 diabetes. Clin J Am Soc Nephrol. 2007 Mar;2(2):366-73. Epub 2007 Jan 3. PMID: 17699436

14)  M de Lordes Lima, T Cruz, J C Pousada, L E Rodrigues, K Barbosa, V Canguçu. The effect of magnesium supplementation in increasing doses on the control of type 2 diabetes. Diabetes Care. 1998 May;21(5):682-6. PMID: 9589224

15) Y Song, K He, E B Levitan, J E Manson, S Liu. Effects of oral magnesium supplementation on glycaemic control in Type 2 diabetes: a meta-analysis of randomized double-blind controlled trials. Cardiovasc Toxicol. 2008;8(3):115-25. Epub 2008 Jul 8. PMID: 16978367

16)  Martha Rodríguez-Morán, Fernando Guerrero-Romero. Oral magnesium supplementation improves insulin sensitivity and metabolic control in type 2 diabetic subjects: a randomized double-blind controlled trial. Diabetes Care. 2003 Apr;26(4):1147-52. PMID: 12663588

17)  F Facchinetti, P Borella, G Sances, L Fioroni, R E Nappi, A R Genazzani. Oral magnesium successfully relieves premenstrual mood changes. Obstet Gynecol. 1991 Aug;78(2):177-81. PMID: 2067759

18)  A F Walker, M C De Souza, M F Vickers, S Abeyasekera, M L Collins, L A Trinca. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. J Womens Health. 1998 Nov;7(9):1157-65. PMID: 9861593

19)  S Quaranta, M A Buscaglia, M G Meroni, E Colombo, S Cella. Pilot study of the efficacy and safety of a modified-release magnesium 250 mg tablet (Sincromag) for the treatment of premenstrual syndrome. Am J Gastroenterol. 2008 Dec;103(12):2972-6. PMID: 17177579

20) M C De Souza, A F Walker, P A Robinson, K Bolland. A synergistic effect of a daily supplement for 1 month of 200 mg magnesium plus 50 mg vitamin B6 for the relief of anxiety-related premenstrual symptoms: a randomized, double-blind, crossover study. J Womens Health Gend Based Med. 2000 Mar;9(2):131-9. PMID: 10746516

21) Thorsten Reffelmann, Till Ittermann, Marcus Dörr, Henry Völzke, Markus Reinthaler, Astrid Petersmann, Stephan B Felix. Low serum magnesium concentrations predict cardiovascular and all-cause mortality. Atherosclerosis. 2011 Jun 12. Epub 2011 Jun 12. PMID: 21703623

22) Andrea Rosanoff, Mildred S Seelig. Comparison of mechanism and functional effects of magnesium and statin pharmaceuticals. J Am Coll Nutr. 2004 Oct;23(5):501S-505S. PMID: 15466951

23)  GreenMedInfo.com, Magnesium’s Hypotensive Properties.

24) GreenMedInfo.com, Magnesium’s Antispasmodic Properties.

25) Joen R Sheu, George Hsiao, Ming Y Shen, Yen M Lee, Mao H Yen . Antithrombotic effects of magnesium sulfate in in vivo experiments. Int J Hematol. 2003 May;77(4):414-9. PMID: 12774935

26) Afshin Samaie, Nabiollah Asghari, Raheb Ghorbani, Jafar Arda. Blood Magnesium levels in migraineurs within and between the headache attacks: a case control study. Pan Afr Med J. 2012 ;11:46. Epub 2012 Mar 15. PMID: 22593782

27) Mahnaz Talebi, Dariush Savadi-Oskouei, Mehdi Farhoudi, Solmaz Mohammadzade, Seyyedjamal Ghaemmaghamihezaveh, Akbar Hasani, Amir Hamdi. Relation between serum magnesium level and migraine attacks. Neurosciences (Riyadh). 2011 Oct ;16(4):320-3. PMID: 21983373

28) Alexander Mauskop, Jasmine Varughese. Why all migraine patients should be treated with magnesium. J Neural Transm. 2012 May ;119(5):575-9. Epub 2012 Mar 18. PMID: 22426836

29)  Fong Wang, Stephen K Van Den Eeden, Lynn M Ackerson, Susan E Salk, Robyn H Reince, Ronald J Elin. Oral magnesium oxide prophylaxis of frequent migrainous headache in children: a randomized, double-blind, placebo-controlled trial. Eur J Endocrinol. 2009 Apr;160(4):611-7. Epub 2009 Jan 29. PMID: 12786918

30) Ali Tarighat Esfanjani, Reza Mahdavi, Mehrangiz Ebrahimi Mameghani, Mahnaz Talebi, Zeinab Nikniaz, Abdolrasool Safaiyan. The effects of magnesium, L-carnitine, and concurrent magnesium-L-carnitine supplementation in migraine prophylaxis. Biol Trace Elem Res. 2012 Dec ;150(1-3):42-8. Epub 2012 Aug 17. PMID: 22895810

31) David W Killilea, Jeanette A M Maier. A connection between magnesium deficiency and aging: new insights from cellular studies. Magnes Res. 2008 Jun;21(2):77-82. PMID: 18705534

32) GreenMedInfo.com, What We Learned From The Accelerated Aging of Astronauts

33) Katja Held, I A Antonijevic, H Künzel, M Uhr, T C Wetter, I C Golly, A Steiger, H Murck. Oral Mg(2+) supplementation reverses age-related neuroendocrine and sleep EEG changes in humans. Pharmacopsychiatry. 2002 Jul;35(4):135-43. PMID: 12163983

34) William J Rowe. Correcting magnesium deficiencies may prolong life. Clin Interv Aging. 2012 ;7:51-4. Epub 2012 Feb 16. PMID: 22379366


Sayer Ji is founder of Greenmedinfo.com, a reviewer at the International Journal of Human Nutrition and Functional Medicine, Co-founder and CEO of Systome Biomed, Vice Chairman of the Board of the National Health Federation, Steering Committee Member of the Global Non-GMO Foundation.


For more info from Greenmedinfo, you can join their newsletter by clicking here.


Link to original article. 

Help Support Collective Evolution

The demand for Collective Evolution's content is bigger than ever, except ad agencies and social media keep cutting our revenues. This is making it hard for us to continue.

In order to stay truly independent, we need your help. We are not going to put up paywalls on this website, as we want to get our info out far and wide. For as little as $3 a month, you can help keep CE alive!

SUPPORT CE HERE!

cards

Continue Reading
advertisement - learn more
advertisement - learn more

Video

Pod